Compare Adaptive Biotechnologies Corp (ADPT) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vital Farms Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.11 (market cap $4.04B), while Vital Farms Inc trades at $11.38 (market cap $496.50M). The key difference: Adaptive Biotechnologies Corp is far larger — about 8.1× Vital Farms Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | VITL | |
|---|---|---|
Market Cap | $4.04B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $52.41 |
52-Week Low | $12.30 | $8.28 |
Enterprise Value | $4.10B | $583.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
VITL trades at $11.35, down 0.8% daily, with a bearish technical signal driven by moving averages. Recent Q2 2026 results showed a loss of $0.47 per share, beating expectations but reflecting revenue declines amid industry oversupply challenges. The company secured a $125 million term loan in August 2026 to bolster liquidity, as net cash flow remained negative. Valuation ratios like P/E of 11.77 and P/S of 0.67 suggest potential undervaluation, but profitability metrics are weak with net income margin at 0.02%.
The outlook is mixed: analyst consensus is bullish with a $13.00 price target, but execution risks from cost pressures and competitive gaps persist. Near-term catalysts include Q3 2026 earnings, while downside risks involve ongoing operational challenges and class-action litigation noted in May 2026. The stock's proximity to its 52-week low underscores cautious sentiment despite institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
